John Carroll

John D. Carroll is a former editor at FierceBiotech.

Stories by John Carroll

Ex-uniQure chief Aldag takes helm at vaccine upstart Hookipa

by John Carroll

Thursday, June 16, 2016

“I enjoy building companies,” notes Jörn Aldag in the lead to his profile note on LinkedIn. And now he’s getting a shot at a new challenge.

Mersana pushes fundraising past $120M, takes aim at the clinic

by John Carroll

Thursday, June 16, 2016

Mersana Therapeutics has teed up its first clinical program for the lead antibody drug conjugate in its pipeline, gaining $33 million in a new round to fund the work.

Szela steers ailing Aegerion into QLT merger, reboots as Novelion

by John Carroll

Wednesday, June 15, 2016

Four months after restructuring the ailing Aegerion ($AEGR) and axing about 80 staffers, CEO Mary Szela has completed the deal she wanted to bring in a late-stage asset.

Rottweiler tested, Novo and Sofinnova back $33M round for Rgenix

by John Carroll

Wednesday, June 15, 2016

Sofinnova Partners' Antoine Papiernek not only agreed to co-lead the $33 million B round, he grabbed a seat on the board along with Nilesh Kumar from co-lead investor Novo A/S.

Infinity Pharma back under a cloud after duvelisib disappoints in PhII

by John Carroll

Tuesday, June 14, 2016

Three years after it was forced to restructure the company in the wake of the failure of its then lead drug, Infinity Pharmaceuticals ($INFI) finds itself in a new crisis.

J&J Innovation backs Gilde’s new $285M biotech fund

by John Carroll

Tuesday, June 14, 2016

Gilde Healthcare has put together its fourth healthcare fund, looking to back a range of biotechs, device companies and digital health with a fresh injection of $285 million.

FDA overrides adcomm, shoots down KemPharm’s opioid

by John Carroll

Monday, June 13, 2016

The biotech says that the agency has decided to slam the door shut on a marketing approval for Apadaz--at least for now.

FDA’s Pazdur chides biopharma for falling into an I/O rut

by John Carroll

Monday, June 13, 2016

Pazdur has some business advice he’d like to give drug developers: Stay focused on the cutting edge, and lose the me-too drugs in the cancer pipeline.

Struggling Eleven Bio cashes out of 2nd drug in $270M Roche deal

by John Carroll

Monday, June 13, 2016

Faced with back-to-back pivotal flops for its lead drug, Eleven Biotherapeutics has now outlicensed the second drug in its limited pipeline to Roche.

Mitch Gold orchestrates $48M round for Alpine’s next-gen immunotherapy play

by John Carroll

Monday, June 13, 2016

The former Dendreon CEO and current venture capitalist has pieced together a $48 million A round for Alpine Immune Sciences in Seattle.

GET THE NEWSLETTER

Subscribe to FierceBiotech to get industry news and updates delivered to your inbox.